Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03253926 · ClinicalTrials.gov registry record · Phase 1

Effect of Lorcaserin on Cannabis Withdrawal and Self-administration

A Phase 1 study of Cannabis Use, sponsored by New York State Psychiatric Institute.

Completed
Registry status
Phase 1
Development phase
15
Enrollment target
1
Study location

NCT03253926 is a Phase 1 study of Cannabis Use that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 15 participants, below the 279-participant average among 44 other Cannabis Use trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03253926, a Phase 1 study of Cannabis Use, has completed, sponsored by New York State Psychiatric Institute.

COMPLETED
Registry status
Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

In this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.

Conditions Studied

Cannabis Use

Interventions

  • DRUG Placebo
  • DRUG Lorcaserin
  • DRUG Marijuana

Study Locations (1)

New York

  • New York State Psychiatric Institute - New York

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2017-09-05
Est. Completion 2021-12-31
Phase Phase 1

Sponsor

New York State Psychiatric Institute

364 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03253926

The ClinicalTrials.gov registry entry for NCT03253926 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 279-participant average among 44 other Cannabis Use trials with a reported enrollment target (95% lower). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cannabis Use appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT03253926 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03253926 about?

NCT03253926 is a clinical study titled "Effect of Lorcaserin on Cannabis Withdrawal and Self-administration". In this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.

What is the current status of trial NCT03253926?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2017-09-05. Estimated completion is 2021-12-31.

What conditions does trial NCT03253926 study?

This clinical trial studies the following conditions: Cannabis Use.

What interventions are being tested in trial NCT03253926?

The interventions under investigation include: Placebo (DRUG), Lorcaserin (DRUG), Marijuana (DRUG).

Who is sponsoring clinical trial NCT03253926?

This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03253926 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cannabis Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cannabis Use

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.